title: Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection.
abstract: Chemosurgical treatment of vaginal/cervical human papillomavirus (HPV) infection with 5-fluorouracil (5-FU) is limited by vulvar pain and dysuria resultant from leakage and vulvar/urethral tissue reaction to the 5-FU. Women with cervical HPV DNA identified by in situ hybridization on colposcopically directed biopsy were treated with topically applied 5% 5-FU cream. A fitted cervical cap was used to restrict exposure to 5-FU. Repeat biopsies and in situ hybridization at least 6 weeks after application failed to detect HPV DNA in 6 of 7 patients. In 1 case, 5-FU treatment was associated with a decreased intensity of detectable HPV DNA. No episodes of vulvar pain or dysuria occurred. 5-FU can be used in the treatment of cervical HPV with minimal side effects when applied utilizing a cervical cap.
authors.affiliation: Colorado Gynecology and Continence Center, Denver, CO 80218, USA.
authors.forename: G W
authors.initials: GW
authors.lastname: Davila
authors.forename: K R
authors.initials: KR
authors.lastname: Shroyer
mesh_terms: D000287:Administration, Topical; D000328:Adult; D001706:Biopsy; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017403:In Situ Hybridization; D027383:Papillomaviridae / Q000235:genetics; D030361:Papillomavirus Infections / Q000188:drug therapy*; D014412:Tumor Virus Infections / Q000188:drug therapy*
chemical_list: D004279:DNA, Viral; D005472:Fluorouracil